404 related articles for article (PubMed ID: 25241734)
1. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?
Lippi G; Favaloro EJ
Clin Chem Lab Med; 2015 Feb; 53(2):185-97. PubMed ID: 25241734
[TBL] [Abstract][Full Text] [Related]
2. Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges.
Favaloro EJ; Pasalic L; Curnow J; Lippi G
Curr Drug Metab; 2017; 18(7):598-608. PubMed ID: 28413976
[TBL] [Abstract][Full Text] [Related]
3. Clinical judgment when using coagulation tests during direct oral anticoagulant treatment: a concise review.
Di Minno A; Spadarella G; Prisco D; Franchini M; Lupoli R; Di Minno MN
Semin Thromb Hemost; 2013 Oct; 39(7):840-6. PubMed ID: 24022805
[TBL] [Abstract][Full Text] [Related]
4. Laboratory measurement of the direct oral anticoagulants.
Dale BJ; Chan NC; Eikelboom JW
Br J Haematol; 2016 Feb; 172(3):315-36. PubMed ID: 26492202
[TBL] [Abstract][Full Text] [Related]
5. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
[TBL] [Abstract][Full Text] [Related]
6. [Direct Oral Anticoagulants (DOACs): Pharmacological Characteristics and Laboratory Assessment].
Kitajima I
Rinsho Byori; 2016 Aug; 64(8):972-979. PubMed ID: 30609341
[TBL] [Abstract][Full Text] [Related]
7. Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors.
Favaloro EJ; Lippi G
Semin Thromb Hemost; 2015 Mar; 41(2):208-27. PubMed ID: 25703514
[TBL] [Abstract][Full Text] [Related]
8. Direct oral anticoagulants (DOACs): From the laboratory point of view.
Margetić S; Goreta SŠ; Ćelap I; Razum M
Acta Pharm; 2022 Dec; 72(4):459-482. PubMed ID: 36651369
[TBL] [Abstract][Full Text] [Related]
9. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
[TBL] [Abstract][Full Text] [Related]
11. Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication.
Cuker A
J Thromb Thrombolysis; 2016 Feb; 41(2):241-7. PubMed ID: 26386967
[TBL] [Abstract][Full Text] [Related]
12. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
13. Screening test for direct oral anticoagulants with the dilute Russell viper venom time.
Pratt J; Crispin P
Eur J Haematol; 2018 Jun; 100(6):567-574. PubMed ID: 29486103
[TBL] [Abstract][Full Text] [Related]
14. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.
Helin TA; Lemponen M; Hjemdahl P; Rönquist-Nii Y; Lassila R; Joutsi-Korhonen L
Thromb Res; 2015 Jul; 136(1):154-60. PubMed ID: 25981140
[TBL] [Abstract][Full Text] [Related]
15. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
[TBL] [Abstract][Full Text] [Related]
16. The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
Buijs JT; Laghmani EH; van den Akker RFP; Tieken C; Vletter EM; van der Molen KM; Crooijmans JJ; Kroone C; Le Dévédec SE; van der Pluijm G; Versteeg HH
J Thromb Haemost; 2019 Jun; 17(6):951-963. PubMed ID: 30929299
[TBL] [Abstract][Full Text] [Related]
17. Direct oral anticoagulants: new drugs and new concepts.
Levy JH; Spyropoulos AC; Samama CM; Douketis J
JACC Cardiovasc Interv; 2014 Dec; 7(12):1333-51. PubMed ID: 25523529
[TBL] [Abstract][Full Text] [Related]
18. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jochmans K; Mullier F; Wijns W; Soumali MR; Coucke W; Vernelen K; Van de Walle P
Thromb Haemost; 2015 Jan; 113(1):154-64. PubMed ID: 25231101
[TBL] [Abstract][Full Text] [Related]
19. The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
Bonar R; Favaloro EJ; Mohammed S; Pasalic L; Sioufi J; Marsden K
Pathology; 2015 Jun; 47(4):355-64. PubMed ID: 25938348
[TBL] [Abstract][Full Text] [Related]
20. Coagulation Testing in the Core Laboratory.
Winter WE; Flax SD; Harris NS
Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
